Mylan Can't Exclude Ex-CEO From EpiPen Antitrust Trial

By Bryan Koenig · January 6, 2022, 5:20 PM EST

A Kansas federal judge Wednesday rejected Mylan's bid to spare a former CEO from the late January trial in a massive antitrust class action accusing the drugmaker of unlawfully blocking generic...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Motion for Clarification

Case Information

Case Title

In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Case Number

Court

Kansas

Nature of Suit

Personal Inj. Prod. Liability

Date Filed

August 04, 2017

Recent Articles By Bryan

July 17, 2024
Heart Doctor's Sham Suit Claims Cut From Antitrust Row
July 11, 2024
Fed. Circ. Pauses Ouster Of Teva Patents From Orange Book
July 08, 2024
Texas Anesthesia Co. Can't Pause Or Appeal Suit, FTC Says
June 27, 2024
EU High Court Upends Servier Decrease Of Pay-For-Delay Fine
June 26, 2024
Apple Watch Improvement Is 'Inferior,' Docs Tell 9th Circ.
June 13, 2024
EU Makes First Ever Formal Pharma Price-Fixing Complaint
June 12, 2024
Texas Anesthesia Co. Appealing To Duck FTC Suit To 5th Circ.
June 10, 2024
Rehab Clinics Add To MultiPlan Insurance Fixing Pile-On
May 22, 2024
Teva, Bristol-Myers Cite Bystolic Against Cancer Drug Case
May 14, 2024
FTC Cleared To Sue Texas Anesthesia Co., But Not PE Firm